Benicar and Platelet count increased - a phase IV clinical study of FDA data

Summary:

Platelet count increased is reported as a side effect among people who take Benicar (olmesartan medoxomil), especially for people who are female, 60+ old, also take Jakafi, and have Polycythaemia vera.

The phase IV clinical study analyzes which people have Platelet count increased when taking Benicar. It is created by eHealthMe based on reports of 34,073 people who have side effects when taking Benicar from the FDA, and is updated regularly.

What is Benicar?

Benicar has active ingredients of olmesartan medoxomil. It is often used in high blood pressure. eHealthMe is studying from 36,002 Benicar users. Check the latest studies of Benicar.

What is Platelet count increased?

Platelet count increased is found to be associated with 957 drugs and 1,190 conditions by eHealthMe. Check the latest studies of Platelet count increased.

On Aug, 01, 2026

34,073 people reported to have side effects when taking Benicar.
Among them, 36 people (0.11%) have Platelet count increased.

Could Benicar cause Platelet count increased?

Among these 36 people:

What is the gender of people who have Platelet count increased when taking Benicar? *

female: 63.64 %
male: 36.36 %

What is the age of people who have Platelet count increased when taking Benicar? *

What are other drugs people take besides Benicar? *

What are other side effects people have besides Platelet count increased? *

Pain: 13 people, 36.11%
Haemoglobin Decreased: 12 people, 33.33%
Fatigue (feeling of tiredness): 12 people, 33.33%
Anaemia (lack of blood): 12 people, 33.33%
Nausea (feeling of having an urge to vomit): 11 people, 30.56%
Urinary Tract Infection: 11 people, 30.56%
Thrombocytopenia (decrease of platelets in blood): 10 people, 27.78%
Red Blood Cell Count Decreased: 10 people, 27.78%
Pain In Extremity: 10 people, 27.78%
Haematocrit Decreased: 9 people, 25.00%

What are the existing conditions these people have? *

Primary Myelofibrosis (primary disorder of the bone marrow): 8 people, 22.22%
Polycythaemia Vera (blood disorder in which the bone marrow makes too many red blood cells): 8 people, 22.22%
Psoriasis (immune-mediated disease that affects the skin): 2 people, 5.56%
Blood Testosterone Decreased: 2 people, 5.56%
Essential Thrombocythaemia (chronic blood cancer): 2 people, 5.56%
Multiple Sclerosis (a nervous system disease that affects your brain and spinal cord. it damages the myelin sheath): 2 people, 5.56%
Thrombocytosis: 1 person, 2.78%
Multiple Myeloma (cancer of the plasma cells): 1 person, 2.78%
Atrial Fibrillation/flutter (atrial fibrillation and flutter are abnormal heart rhythms in which the atria, or upper chambers of the heart, are out of sync with the ventricles): 1 person, 2.78%
Diabetes: 1 person, 2.78%

* Approximation only. Some reports may have incomplete information.

Do you take Benicar and have Platelet count increased?

- Check whether Platelet count increased is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Benicar:

Benicar (36,002 reports)

Browse all side effects of Benicar:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Platelet count increased:

Platelet count increased (957 drugs)

Browse all the conditions that are associated with Platelet count increased:

Platelet count increased (1,190 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on olmesartan medoxomil (the active ingredients of Benicar) and Benicar (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.